What You Should Know:
- Cedars-Sinai Cancer and Tempus, a provider of artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients' DNA, RNA, protein and other information to help identify the most effective approach to each individual's disease.
- By creating these "molecular twins," scientists can genetically classify cancer genes and proteins of particular tumors
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
H1 Launches Solution to Build More Inclusive, Successful Clinical Trials
What You Should Know:
- H1, which provides the largest global healthcare platform connecting the healthcare ecosystem, announced today that it has launched H1 Trial Landscape, the first solution that not only helps pharma and life sciences companies determine the required clinical experience levels for their clinical trials, but also enables them to find the best patient segments to improve inclusivity, retention and recruitment for successful trials.
- Studies have shown that more than
Read More
Clinical Trials: 4 Strategies to Maximize Patients Referrals
Clinical trials were front and center in 2020, as pharma companies raced to develop and prove the safety and efficacy of their COVID-19 vaccines. Despite this increased awareness, many potential participants and referring clinicians remain unaware of available trials and how to become involved. This negatively impacts enrollment efficiency and overall study timelines.
Enter patient referral platforms. The growth of these third-party services has helped bridge the knowledge gap for both
Read More
Fresenius Medical Invests Additional $25M in Biotech Platform Humacyte
What You Should Know:
Fresenius Medical Care (FMC) today announced its plans to invest an additional $25 million in clinical-stage biotechnology platform company Humacyte following the extension of its collaboration in June. Fresenius Medical Care acquired a stake in Humacyte in 2018 for $150M as part of a strategic partnership.
Following the merger of Humacyte with a special purpose acquisition company (SPAC), FMC is increasing its position in the newly combined
Read More
Ontada, Merck Partner to Facilitate Real World Evidence Studies for Cancer Care
What You Should Know:
- Ontada, McKesson’s oncology and insights business, announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation. This agreement enables the two healthcare leaders to harness the power of real-world evidence (RWE) towards the common goal of improving patient outcomes and the quality of cancer care.
- Ontada and Merck’s combined experience and
Read More
Why We Need a Personalized Approach to COVID-19 Immunity Testing
To date, the battle against COVID-19 has been waged largely in the field of public health, using a series of binary, black-and-white thresholds to measure progress. The number of positive cases per 100,000 people, yes/no results on PCR tests, absence or presence of antibodies – these have set the benchmarks used to determine when we can open our schools and restaurants, remove our masks and resume something resembling our old routines.
While these numbers do tell us something about the
Read More
Curebase, AppliedVR Partner on Multiple VR Therapy Clinical Trials
What You Should Know:
- Curebase, a company committed to democratizing access to clinical studies, and AppliedVR, a pioneer advancing the next generation of digital medicine, today announced a one-year partnership where AppliedVR will deploy the Curebase platform to run five clinical trials assessing the effectiveness of virtual reality-based (VR) therapy to treat chronic pain.
- AppliedVR is the most evidence-based therapeutic VR platform for pain management and has been used by
Read More
ConcertAI, Janssen Partner to Address Health Disparities in Clinical Trials
What You Should Know:
- ConcertAI, a leader in RWD and enterprise AI tech for oncology, announced the expansion of its multi-year collaboration with Janssen. The expanded collaboration aims to further the novel work that the two companies’ are doing to broaden access to trials in new sites and strengthen trial diversity.
- This expanded collaboration, which combines ConcertAI’s broad data sets with the expertise of Janssen’s data science team, aims to advance innovative insights that
Read More
AllStripes Secures $50M to Advance Global Rare Disease Research Platform
- AllStripes, a San Francisco-based healthcare technology company dedicated to unlocking treatments for people affected by rare diseases, today announced it has raised $50 million in Series B funding led by Lux Capital, a current investor, joined by JAZZ Venture Partners, Spark Capital, Medidata Solutions, McKesson Ventures, and Maveron. The round also included participation from angel investors including Arif Nathoo, CEO of Komodo Health, and Leila Zegna, Director
Read More
UPMC Launches Drug Discovery Company Novasenta to Develop Targeted Immunotherapy Drugs for Cancer
What You Should Know:
- UPMC today announced the launch of Novasenta, a drug discovery and development company seeking novel and effective treatments for cancer. Co-founded in late 2018 by Robert Ferris, M.D., Ph.D., Dario Vignali, Ph.D., and Greg Delgoffe, Ph.D., all of the UPMC Hillman Cancer Center and Pitt, Novasenta is currently focused on T-cell targets and rapidly advancing programs with the goal of launching its first clinical trial by the end of 2023.
- Based on years
Read More
